Clifton E. Barry

50.3k citations

287 papers · 28.9k indexed · 8 hit papers · h-index 93

Impact in

Infectious Diseases top 0.01%
- Tuberculosis Research and Epidemiology
Molecular Medicine top 0.05%
- Antibiotic Resistance in Bacteria

Papers in

Infectious Diseases 209
- Tuberculosis Research and Epidemiology 207
Molecular Medicine 32
- Antibiotic Resistance in Bacteria 32

Co-authors: Helena I. Boshoff Laura E. Via Véronique Dartois Richard A. Slayden Gilla Kaplan Michael B. Reed JoAnne L. Flynn Claudia Manca
Journals: Antimicrobial Agents and Chemotherapy (18 papers)Proceedings of the National Academy of Sciences (17 papers)Journal of Medicinal Chemistry (14 papers)Journal of Biological Chemistry (11 papers)Journal of Bacteriology (11 papers)
Partner nations: United States South Africa United Kingdom

In The Last Decade

Clifton E. Barry

284 papers receiving 28.4k citations

Hit Papers

8 papers align trajectories log scale

Tuberculosis 2015 · 401 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 The Lancet
2014 Nature
2012 Antimicrobial Agents and Chemotherapy
2011 Science
2009 Nature Reviews Microbiology
2008 Infection and Immunity
2004 Nature
2000 Nature

Peers

Countries citing papers authored by Clifton E. Barry

Since Specialization

Citations

This map shows the geographic impact of Clifton E. Barry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clifton E. Barry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clifton E. Barry more than expected).

Fields of papers citing papers by Clifton E. Barry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clifton E. Barry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clifton E. Barry. The network helps show where Clifton E. Barry may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Clifton E. Barry, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Clifton E. Barry Line = papers co-authored together Clifton E. Barry links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Systematic Approach to Discover New Natural Product Scaffolds Using Database-Derived Relative Mass Spectral Defects and Molecular Networking JACS Au ·Hyo Moon Cho, Jorge Cuadras, Mathilda Monaghan, بهروز رضایی منش, Helena I. Boshoff, Clifton E. Barry, Giuseppe Bifulco, Carole A. Bewley	2025	0
2	The Kinetics of Bedaquiline Diffusion in Tuberculous Cavities Open a Window for the Emergence of Resistance The Journal of Infectious Diseases ·Annamarie E. Bustion, M S Quesada, Firat Kaya, 焦成根, Jansy P. Sarathy, Landry Blanc, Marjorie Z. Imperial, Martin Gengenbacher, Min Xie, Matthew Zimmerman, Gregory T. Robertson, Dominique J. Wiener, Laura E. Via, Clifton E. Barry, Radojka M. Savić, Véronique Dartois	2025	0
3	The Antitubercular Activities of Natural Products with Fused-Nitrogen-Containing Heterocycles Pharmaceuticals ·Helena I. Boshoff, Neha Malhotra, Clifton E. Barry, Sangmi Oh	2024	6
4	A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial Nature Medicine ·Andreas H. Diacon, Clifton E. Barry, Gustav Eberhard, Ray Y. Chen, Amaury Dalla Monta, Veronique de Jager, Klaas R. Timmermans, Gavin Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, В.П. Попов, Rhona Scott, Gareth Maher‐Edwards, Simon Tiberi, Ryuji Kobori, Caryn M. Upton, David Barros-Aguirre	2024	20
5	Structure–Activity Relationships of Pyrazolo[1,5-a]pyrimidin-7(4H)-ones as Antitubercular Agents ACS Infectious Diseases ·Sangmi Oh, M. Daben J. Libardo, Shaik Azeeza, Gary T. Pauly, C. Volker, Andaleeb Sajid, Yoshitaka Tateishi, Caroline J. Duncombe, Michael Goodwin, Thomas R. Ioerger, Paul G. Wyatt, Peter C. Ray, David W. Gray, Helena I. Boshoff, Clifton E. Barry	2021	13
6	Signature required: The transcriptional response to tuberculosis The Journal of Experimental Medicine ·Clifton E. Barry, Katrin D. Mayer-Barber	2021	3
7	Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor Response Cancer Immunology Research ·Benjamin Ruf, D. M. Dubkov, Simon Wabitsch, Chi Ma, Laurence P. Diggs, Qianfei Zhang, Bernd Heinrich, Varun Subramanyam, Linda L. Cui, Marie Pouzolles, Christine N. Evans, Raj Chari, Shunsuke Sakai, Sangmi Oh, Clifton E. Barry, Daniel L. Barber, Tim F. Greten	2021	39
8	Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development Nature Communications ·将史高見, Kathryn O’Brien, Divya Tiwari, Curtis A. Engelhart, Shaun B. Walters, 邓阿丽, Hee‐Jeong Yang, 原田やよい, Dominique J. Wiener, Emmanuel K. Dayao, Matthew Zimmerman, Brendan Prideaux, Prashant Desai, Thierry Masquelin, Laura E. Via, Véronique Dartois, Helena I. Boshoff, Clifton E. Barry, Sabine Ehrt, Dirk Schnappinger	2019	86
9	Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: A mechanistic model and tool for regimen and dose optimization PLoS Medicine ·Natasha Strydom, Sneha Gupta, Melissa Kuznik, Laura E. Via, Hyeeun Bang, Myungsun Lee, Seok‐Yong Eum, Tae Sun Shim, Clifton E. Barry, Matthew Zimmerman, Véronique Dartois, Radojka M. Savić	2019	134
10	Role of Chemical Biology in Tuberculosis Drug Discovery and Diagnosis ACS Infectious Diseases ·Katharina Kolbe, Tomáš Najbrt, Érika de Sousa Mendonça, Kazumi Katagiri, Sangmi Oh, Clifton E. Barry	2018	12
11	Discovery and Structure–Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2′-Oxidase Journal of Medicinal Chemistry ·Sangmi Oh, Yumi Park, Curtis A. Engelhart, Joshua B. Wallach, Dirk Schnappinger, Kriti Arora, Yu-Xiong Yan, R. Karthikeyani, Hongwu Wang, Nicholas Murgolo, David B. Olsen, Michael Goodwin, S D Ding, Dominique J. Wiener, Laura E. Via, Helena I. Boshoff, Clifton E. Barry	2018	29
12	Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum Antimicrobial Agents and Chemotherapy ·Jansy P. Sarathy, Laura E. Via, Dominique J. Wiener, Landry Blanc, Helena I. Boshoff, Eliseo A. Eugenín, Clifton E. Barry, Véronique Dartois	2017	159
13	A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence Proceedings of the National Academy of Sciences ·Jee-Hyun Kim, Kathryn O’Brien, Ritu Sharma, Helena I. Boshoff, Germán Rehren, Sumit Chakraborty, Joshua B. Wallach, Mercedes Monteleone, Daniel J. Wilson, Courtney C. Aldrich, Clifton E. Barry, Kyu Y. Rhee, Sabine Ehrt, Dirk Schnappinger	2013	102
14	Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis Science ·Wanliang Shi, Xuelian Zhang, Xin Jiang, Haiming Yuan, Jong Seok Lee, Clifton E. Barry, Honghai Wang, Wenhong Zhang, Ying Zhang Hit paper breakdown →	2011	392
15	The Three RelE Homologs of Mycobacterium tuberculosis Have Individual, Drug-Specific Effects on Bacterial Antibiotic Tolerance Journal of Bacteriology ·Ramandeep Singh, Clifton E. Barry, Helena I. Boshoff	2010	112
16	Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis Science ·Jean‐Emmanuel Hugonnet, L.W. Tremblay, Helena I. Boshoff, Clifton E. Barry, John S. Blanchard	2009	382
17	Expansion of the mycobacterial “PUPylome” Molecular BioSystems ·Jeramie D. Watrous, Kristin E. Burns, Wei-Ting Liu, Anand Patel, Vivian Hook, Vineet Bafna, Clifton E. Barry, Tri Sudibyou, Pieter C. Dorrestein	2009	73
18	PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release Science ·Ramandeep Singh, Ujjini H. Manjunatha, Helena I. Boshoff, Nada Ata Allah, Pornwaratt Niyomrattanakit, Richard Ledwidge, Cynthia S. Dowd, Ill Young Lee, Pilho Kim, Liang Zhang, Sun‐Hee Kang, Thomas H. Keller, Jan Jiřiček, Clifton E. Barry	2008	491
19	Mycobacterium tuberculosis Growth at theCavity Surface: a Microenvironment with FailedImmunity Infection and Immunity ·Gilla Kaplan, Frank A. Post, André L. Moreira, Helen Wainwright, Barry N. Kreiswirth, M. Tanverdi, Barun Mathema, Srinivas V. Ramaswamy, 格三上, Lafras M. Steyn, Clifton E. Barry, Linda‐Gail Bekker	2003	277
20	Virulence of aMycobacterium tuberculosisclinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β Proceedings of the National Academy of Sciences ·Claudia Manca, Liana Tsenova, Amy Bergtold, Sherry Freeman, Michaël G. Tovey, James M. Musser, Clifton E. Barry, Victoria H. Freedman, Gilla Kaplan	2001	483

About Clifton E. Barry

Clifton E. Barry is a scholar working on Infectious Diseases, Molecular Medicine, Epidemiology, Molecular Biology and Surgery, having authored 287 papers that have together received 28.9k indexed citations. Recurring topics across this work include Tuberculosis Research and Epidemiology (207 papers), Mycobacterium research and diagnosis (126 papers), Cancer therapeutics and mechanisms (49 papers), Biochemical and Molecular Research (42 papers), Pneumocystis jirovecii pneumonia detection and treatment (34 papers), Antibiotic Resistance in Bacteria (32 papers), Infectious Diseases and Tuberculosis (31 papers) and Diagnosis and treatment of tuberculosis (28 papers). The work is most often cited by research in Infectious Diseases (19.4k citations), Molecular Medicine (3.0k citations), Epidemiology (14.5k citations), Molecular Biology (11.2k citations) and Immunology (2.9k citations). Clifton E. Barry has collaborated with scholars based in United States, South Africa and United Kingdom. Frequent co-authors include Helena I. Boshoff, Laura E. Via, Véronique Dartois, Richard A. Slayden, Gilla Kaplan, Michael B. Reed, JoAnne L. Flynn, Claudia Manca, Ying Yuan and David R. Sherman. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Proceedings of the National Academy of Sciences, Journal of Medicinal Chemistry, Journal of Biological Chemistry and Journal of Bacteriology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact